Pfizer Covid Pill Access Stymied by ‘Vague’ Prescribing Guidance

June 3, 2022, 9:35 AM UTC

High-risk Americans are having a tough time getting Covid-19 antiviral pills as prescribers grapple with limited guidance on who is eligible and how many are available, infectious disease specialists say.

More than 2,500 Test-to-Treat sites are set up across the country where patients can get tested and prescribed Pfizer Inc.‘s Paxlovid or Merck & Co.’s molnupiravir by a health provider at a single location. But some providers are reluctant to prescribe the pills due to uncertainty over how they interact with other drugs, how to apply the risk factors that qualify people for the treatment, and limited awareness ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.